<DOC>
	<DOCNO>NCT01213043</DOCNO>
	<brief_summary>This study ass safety pharmacokinetics weekly infusion 120 mg/kg Prolastin-C ( alpha1-proteinase inhibitor [ alpha1-PI ] [ Human ] ) , compare weekly infusion 60 mg/kg Prolastin-C patient alpha 1-antitrypsin deficiency ( AATD ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics Alpha-1 Proteinase Inhibitor Subjects With Alpha1-Antitrypsin Deficiency</brief_title>
	<detailed_description>The question whether high dos alpha1-PI ( &gt; 60 mg/kg ) able provide good protection patient alpha 1-antitrypsin deficiency currently unknown . As first step address question , present study undertaken . This multi-center , randomize , double-blind , crossover study assess safety pharmacokinetics weekly infusion 120 mg/kg Prolastin-C , compare weekly infusion 60 mg/kg Prolastin-C patient alpha 1-antitrypsin deficiency . This study crossover design 2 treatment sequence : Treatment Sequence 1 : 60 mg/kg weekly infusion Prolastin-C 8 week follow 120 mg/kg weekly infusion Prolastin-C 8 week ( start Week 1 ) ( total 16 treatment week ) Treatment Sequence 2 : 120 mg/kg weekly infusion Prolastin-C 8 week follow 60 mg/kg weekly infusion Prolastin-C 8 week ( start Week 11 ) ( total 16 treatment week ) Approximately 15 subject plan enter treatment sequence . At Weeks 8 11 Weeks 18 21 , total 15 serial blood sample subject draw pharmacokinetic analysis . The expected duration study subject 's participation approximately 25 week ( include 3-Week Screening Phase , 2-Week Washout Period [ different alpha-1 PI treatment dose ] , 4-Week Follow-up Period ) . The following safety parameter assess : adverse event , pulmonary exacerbation , vital sign , pulmonary function test , clinical laboratory test .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Be 18 70 year age Have document diagnosis congenital AATD Have postbronchodilator Forced Expired Volume 1 second ( FEV1 ) â‰¥30 % &lt; 80 % FEV1/forced vital capacity ( FVC ) &lt; 70 % If receive alpha1 PI augmentation therapy , willing discontinue treatment duration study Had moderate severe pulmonary exacerbation 4 week study History lung liver transplant Any lung surgery past 2 year Confirmed liver cirrhosis Elevated liver enzymes Severe concurrent disease Females pregnant breastfeeding unwilling practice effective contraception study Infection hepatitis A , B , C , human immunodeficiency parvovirus B19 Smoking past 6 month Use systemic steroid within 4 week study Use antibiotic exacerbation within 4 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>emphysema</keyword>
	<keyword>alpha 1-antitrypsin</keyword>
	<keyword>alpha 1-antitrypsin deficiency ( AATD )</keyword>
	<keyword>alpha 1-proteinase inhibitor ( Alpha-1 PI )</keyword>
</DOC>